for:

)

Appendix 5: Pharmaceutical opinion sample

FAX

то:	FROM: Pharmacist's Name
FAX:	PAGES:
RE: Deprescribing PPI for:	DATE:

Dear Dr. _____,

We met with ______ for a medication review and are writing regarding PPI deprescribing. According to the patient, they do not have a history of Barrett's esophagus or bleeding GI ulcer, chronic NSAID use, or severe esophagitis, which would warrant long-term use.

S/he has been taking _____

(reason and length of time).

Since long-term use does not seem necessary and PPIs are associated with vitamin B12 deficiency, hypomagnesia, fractures, *C.difficile* infections and community-acquired pneumonia, I suggest (check the following that apply):

Stop PPI (rationale:	

- Decrease to a lower dose_____
- Stop daily use. Recommend daily use if symptoms return and stop when symptoms subside. Approx 1/10 may have return of symptoms. (i.e., the Stop And Use On Demand Method)
- Use non-drug approaches for heartburn: avoid meals 2-3 hours per bed, elevate bed, weight loss if applicable, avoid dietary triggers

We will follow up at 4 and 12 weeks after dose reduction or cessation for heartburn, regurgitation, dyspepsia, and epigastric pain. If symptoms recur, we may suggest OTC antacids or contact you as needed.

If you have conflicting information regarding the patient's history or reason for taking this medication, or have any other questions or concerns, please contact me at ______.

The PPI evidenced-based deprescribing guideline is published here: <u>http://www.cfp.ca/content/63/5/354</u> and an algorithm outlining deprescribing recommendations and a whiteboard video with case examples is available here: <u>https://deprescribing.org/resources/deprescribing-guidelines-algorithms/</u>

Thank you,

Pharmacist's Name, RPh

CONFIDENTIALITY NOTICE — The information contained in this transmission is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. If you are not the intended recipient of this information, do not review, re-transmit, disclose, disseminate, use, or take any action in reliance upon, this information. If you received this transmission in error, please contact XXXXXXXXXXXXXX further instruction.

Farrell B et al. Community pharmacists as catalysts for deprescribing: an exploratory study using quality improvement processes. *Can Pharm J* (Ott) 2020;153(1). DOI: 10.1177/1715163519882969.